论文部分内容阅读
目的 探讨生长抑素治疗急性胰腺炎的临床效果。方法 应用人工合成的生长抑素类似物———奥曲肽治疗急性胰腺炎患者 38例 ,结果与 5 9例非奥曲肽治疗组对照。观察了两组以及奥曲肽治疗前后血清淀粉酶及腹腔液淀粉酶的含量 ,比较两组并发症的发生率。结果 奥曲肽治疗组中 ,17例急性水肿性胰腺炎 (AEP)患者、2 1例急性坏死性胰腺炎 (ANP)患者血清淀粉酶及 19例ANP患者腹腔液淀粉酶含量在治疗前分别为 :(932± 6 7)IU/L、(12 47± 43)IU/L、(988± 47)IU/L ;治疗后 48h分别为 (2 74± 5 7)IU/L、(432± 37)IU/L、(176± 32 )IU/L ,治疗前后差异均有显著意义 (P均 <0 0 5 )。奥曲肽治疗组中 2 1例ANP患者发生并发症 18例次 ,非奥曲肽治疗组 2 6例ANP患者发生并发症 38例次。结论 奥曲肽能有效降低血清淀粉酶和腹腔液淀粉酶的活性 ,改善临床症状 ,降低并发症的发生率。
Objective To investigate the clinical effect of somatostatin in the treatment of acute pancreatitis. Methods Thirty-eight patients with acute pancreatitis were treated with the synthetic analog of somatostatin --- octreotide, and the results were compared with that of the non-octreotide treatment group. The levels of serum amylase and peritoneal amylase in the two groups before and after octreotide treatment were compared, and the complication rates were compared between the two groups. Results In the octreotide treatment group, the amylase levels of peritoneal fluid in 17 patients with acute edematous pancreatitis (AEP), 21 patients with acute necrotizing pancreatitis (ANP) and 19 patients with ANP were (:( 932 ± 6 7), IU / L (12 47 ± 43) IU / L and (988 ± 47) IU / L, respectively / L, (176 ± 32) IU / L, before and after treatment were significantly different (all P <0 05). Among the 21 patients with ANP in the octreotide treatment group, 18 cases were complicated with complications, and 26 cases with ANP in the non-octreotide treatment group were complicated with 38 cases. Conclusion Octreotide can effectively reduce the activity of serum amylase and peritoneal amylase, improve clinical symptoms and reduce the incidence of complications.